Evidence map›Paper›PMID 39282753›Full record

ArticleCancer science2024

RETRACTION: Zebularine Enhances Apoptosis of Human Osteosarcoma Cells by Suppressing Methylation of ARHI.

Abstract readRetraction Notice
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

retractionK. Ye, S. Wang, J. Wang, H. Han, B. Ma and Y. Yang, "Zebularine Enhances Apoptosis of Human Osteosarcoma Cells by Suppressing Methylation of ARHI," Cancer Science 107, no. 12 (2016): 1851-1857, https://doi.org/10.1111/cas.13088. The above article, published online on 29 September 2016 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Masanori Hatakeyama; the Japanese Cancer Association; and John Wiley & Sons Australia, Ltd. The retraction has been agreed following an investigation into concerns raised by a third party, which revealed that the western blots presented in figure 4a and 4d contain duplicated bands. Furthermore, duplications were found between bands within figure 4d itself, some of which appear to have been horizontally flipped. The authors did not respond to the concerns raised and did not provide their original data. The editors consider the results and conclusion reported in this article unreliable.

Identifiers

PMID39282753
PMCPMC11611752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.